UK Community Advisory Board (UK-CAB)

UK-CAB 70: Ageing, polypharmacy and POPPY study community feedback

Friday 15 November 2019


09.30-09.40 Arrival, tea and refreshments
09:40-10:00 Welcome and introductions
UK-CAB updates
Company pre-meeting
10:00-11:15 Company meeting: MSD
11.15-11.30 Break
11.30-12.30 Polypharmacy – Marta Boffito, Chelsea and  Westminster Foundation Hospital
12.45-14.00 Lunch
14.00-16.30 POPPY study community feedback – Alan Winston and Caroline Sabin
16.30-16.30 Break
16.30-17.00 Members Updates
Any other business & reflection
17.00 Meeting close

Slides and meeting report

Polypharmacy – Marta Boffitto, Chelsea and Westminster Foundation Hospital
POPPY study slides – to follow
Meeting report to follow

Background reading and videos/webcasts

The POPPY study

i-Base reports from the 10th International Workshop on HIV and Ageing

Frailty in HIV care and the importance of lifestyle changes

The challenges of HIV treatment in an era of polypharmacy

The Next Therapeutic Challenge in HIV: Polypharmacy

Financial support

The UK-CAB receives unrestricted funding from some pharmaceutical companies towards the direct costs of holding four meetings each year.

This funding supports the travel and accommodation costs for members to attend from outside London, plus the cost of catering. The content, programme and agenda for meetings is decided by the UK-CAB steering group in consultation with the wider membership. Funding is unconnected to meeting content.

Companies that develop and market medicines have a responsibility to actively engage with advocacy organisations. HIV positive people and their advocates should also be able to ask manufacturers directly about the safety and efficacy of their products. We should be involved in their proposals for future research.

For a list of companies that support the UK-CAB please see the “about us” page.